Drug updated on 4/29/2024
Dosage Form | Tablet (oral; 4.5 mg, 9 mg, 13.5 mg) |
Drug Class | Kinase inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
- Indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Pemazyre (pemigatinib) Prescribing Information. | 2023 | Incyte Corporation, Wilmington, DE |
Randomized Controlled Trials
Document Title | Sex Distribution | Year | Source |
---|---|---|---|
Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201. | Data not availableSubjects F: null% M: null% | 2024 | Annals of Oncology |
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. | Data not availableSubjects F: null% M: null% | 2020 | The Lancet. Oncology |
Sex Distribution:
Year:
2024
Source:Annals of Oncology
Sex Distribution:
Year:
2020
Source:The Lancet. Oncology